{"url":"https://whatshealthyandwhy.com/nmn/nad-precursor-and-longevity","path":"/nmn/nad-precursor-and-longevity","alternates":{"json":"https://whatshealthyandwhy.com/api/articles/nmn/nad-precursor-and-longevity.json","markdown":"https://whatshealthyandwhy.com/nmn/nad-precursor-and-longevity.md"},"topic":{"slug":"nmn","name":"NMN","url":"https://whatshealthyandwhy.com/nmn"},"slug":"nad-precursor-and-longevity","order":1,"title":"NAD+ Precursor and Longevity","question":"Does NMN improve insulin sensitivity, physical performance and healthy aging?","answer":"NMN likely improves muscle insulin sensitivity and some strength measures, but trials are small and short, and effects on aging itself are unproven.","description":"How nicotinamide mononucleotide boosts NAD+ levels, supports mitochondrial energy, insulin sensitivity, and healthy aging — and what the human trials show","confidence":3,"confidenceNote":"Placebo-controlled trials of 25, 30 and 80 people, up to 12 weeks, found better insulin sensitivity or strength; the 10-person long-term study lacked placebo.","evidenceSummary":{"rctCount":4,"observationalCount":0,"metaAnalysisCount":0,"totalParticipants":"~185","replicated":true,"newestStudyYear":2024},"category":{"categoryTitle":"What's Good For You","categorySlug":"good-for-you","subcategoryName":"Supplements & Vitamins","subcategorySlug":"supplements","url":"https://whatshealthyandwhy.com/explore/good-for-you/supplements"},"actions":["Trials used 250–600 mg/day for metabolic and performance effects; 600 mg/day was the best dose for physical performance in a 60-day trial [4].","Many people take it in the morning; taking it with or without food appears equivalent.","Do not count on food: edamame, broccoli, cucumber, avocado and tomatoes contain NMN, but far too little to raise blood NAD+."],"cautions":["Safety is documented up to 1,250 mg as a single dose and 500 mg/day for 12 weeks; longer-term effects are unknown [3].","Trials in diabetes used NMN on top of standard care, so do not replace diabetes treatment with it [5]."],"simpleText":"NMN (nicotinamide mononucleotide) is a molecule your body naturally produces and uses to make NAD+ — a coenzyme that every cell needs to generate energy, repair DNA, and regulate hundreds of enzymes. NAD+ levels fall by roughly half between your twenties and fifties, and this decline is increasingly linked to the metabolic and cellular changes associated with aging [6]. By supplying NMN directly, you give your body a ready building block to replenish NAD+ without the bottlenecks that slow other pathways. Early human clinical trials confirm that NMN raises blood NAD+ metabolites [1], improves muscle insulin sensitivity [2], and supports physical performance in middle age [4] — all with a clean safety profile [3].","mediumText":"How NMN Works\n\nNAD+ (nicotinamide adenine dinucleotide) is one of the most fundamental molecules in biology. It sits at the center of metabolism, shuttling electrons during energy production, activating sirtuins (enzymes that regulate cellular repair and longevity), and fueling PARP enzymes that fix DNA damage after oxidative stress or UV exposure [6].\n\nYour body makes NAD+ through several pathways. The main one — the salvage pathway — starts with nicotinamide (a form of vitamin B3) and converts it through a series of steps into NAD+. NMN slots into this pathway one step ahead of NAD+ itself, bypassing some of the rate-limiting steps that can slow conversion. Once absorbed, NMN enters cells via a dedicated transporter (Slc12a8 in rodents, with evidence of analogous transport in human intestinal tissue) and is rapidly converted to NAD+ inside [6].\n\nThe NAD+ decline with age is not subtle. Studies in humans and animals show that NAD+ levels in muscle, liver, and skin fall by 40–60% between young adulthood and middle age, correlating with declines in mitochondrial function, insulin sensitivity, and DNA repair capacity [2]. This decline appears to result from both slower NAD+ synthesis and faster consumption by inflammatory enzymes (CD38) that accumulate with age and chronic inflammation.\n\nWhat the Science Shows\n\nEnergy and metabolism. NAD+ is essential for mitochondrial function. As levels fall, mitochondria produce ATP less efficiently — one reason older adults experience fatigue and reduced exercise tolerance. Restoring NAD+ with NMN in aging animal models reliably improved mitochondrial function, and human trials now show blood NAD+ metabolite increases after oral supplementation [1][7].\n\nInsulin sensitivity. A landmark 2021 trial published in Science found that 250 mg/day NMN for 10 weeks significantly increased skeletal muscle insulin sensitivity in postmenopausal women with prediabetes — measured via hyperinsulinemic-euglycemic clamp, the gold standard method [2]. Muscle gene expression analysis showed upregulation of pathways involved in glucose uptake and insulin signaling. This is the most rigorous human metabolic NMN trial to date.\n\nPhysical performance. A dose-finding trial in healthy middle-aged adults (40–65 years) found that 600 mg/day NMN for 60 days improved muscle strength and performance measures compared to placebo, with a dose-response pattern where 600 mg/day outperformed both lower and higher doses [4]. A separate trial in older adults with diabetes and physical impairment found improvements in grip strength and walking speed with 250 mg/day NMN over 12 weeks [5].\n\nSleep and metabolism. A 12-week trial in healthy middle-aged men found that long-term NMN supplementation improved sleep quality scores alongside NAD+ metabolite elevation, and was associated with beneficial changes in blood glucose and lipid metabolism [7].\n\nNMN vs. NR: Which NAD+ Precursor?\n\nNMN is closely related to NR (nicotinamide riboside), another popular NAD+ precursor. NR is converted to NMN in cells before being used to make NAD+. Both raise NAD+ levels effectively in humans, but they differ in:\n\n- Size. NMN is slightly larger. Some research suggested NMN might not survive the intestine intact, but newer studies confirm oral NMN does raise blood NAD+ metabolites, likely via intestinal transport mechanisms [1][6].\n- Cost. NR supplements are generally less expensive.\n- Bioavailability. A direct head-to-head comparison in humans is still lacking. Both appear effective at raising blood NAD+ metabolites in clinical trials.\n- Research depth. NR has a somewhat larger body of published human trials, though high-quality NMN trials have accelerated since 2021.\n\nFor most people, either precursor is a reasonable choice. NMN may have advantages in tissues expressing the Slc12a8-type transporter, while NR's smaller size may confer advantages in other tissues [6].\n\nDosage and Practical Use\n\nHuman trials have used 250–1,250 mg/day. The most studied range for metabolic and performance effects is 250–600 mg/day. The 2023 dose-finding trial identified 600 mg/day as the apparent sweet spot for physical performance outcomes in middle-aged adults [4]. Safety testing at doses up to 1,250 mg/day for 4 weeks found no serious adverse effects, with blood chemistry and vitals remaining normal [3].\n\nNMN is generally taken in the morning, since NAD+ is involved in circadian signaling. Taking it with or without food appears equivalent based on current data. Most capsule and sublingual forms have demonstrated efficacy in trials.\n\nNMN is a food compound found in small amounts in edamame, broccoli, cucumber, avocado, and tomatoes — but dietary intake is far too low (nanograms to micrograms) to meaningfully raise blood NAD+ levels. Supplementation is the only practical way to deliver gram-range doses.\n\nSee our CoQ10 page and mitochondrial health page for related approaches to cellular energy.","deepText":"Evidence Review\n\nFirst Human NMN Dosing Study (Irie et al., 2020)\n\nThe first-in-human oral NMN study administered single doses of 100, 250, or 500 mg NMN to 10 healthy Japanese men and monitored safety and NAD+ metabolite changes for 5 hours post-dose [1]. No adverse changes were seen in vital signs, blood glucose, oxygen saturation, body temperature, or 44 blood chemistry markers across all doses. Urinary and blood NAD+ metabolites (NAM, NAAD, MeNAM, MeNAM, NMN itself) rose dose-dependently, confirming that oral NMN is absorbed and metabolically active in humans. This established the foundational safety and pharmacokinetic profile for human NMN trials. Limitations: single-dose design, all-male cohort, small sample size (n=10), no placebo comparison.\n\nMuscle Insulin Sensitivity RCT (Yoshino et al., 2021)\n\nPublished in Science, this 10-week double-blind RCT enrolled 25 postmenopausal women with prediabetes (BMI 25–40, impaired fasting glucose) [2]. Thirteen received 250 mg/day NMN and 12 received placebo. Muscle insulin sensitivity was assessed by hyperinsulinemic-euglycemic clamp with stable isotope tracer — the most rigorous available method. NMN significantly increased skeletal muscle insulin-stimulated glucose disposal (Rd; 1.4-fold, p<0.05) compared to placebo. Skeletal muscle RNA sequencing revealed that NMN upregulated expression of genes involved in muscle remodeling and glucose metabolism, particularly SIRT1 and insulin signaling pathways. Blood NAD+ metabolites rose significantly. No changes in body weight, adiposity, blood pressure, or adverse events were observed. Key limitation: 250 mg/day is a low dose; larger trials with higher doses are needed. This remains the highest-quality metabolic NMN trial in humans.\n\nSafety RCT (Fukamizu et al., 2022)\n\nThis 12-week, randomized, double-blind, placebo-controlled trial tested 250 or 500 mg/day NMN in 31 healthy adult men and women (40–65 years) [3]. A separate single-dose arm tested up to 1,250 mg. Safety outcomes included 117 blood chemistry parameters, electrocardiography, ophthalmology, vital signs, and adverse event reporting. No serious adverse events occurred at any dose. Mild, transient events (headache, fatigue) were equally distributed between NMN and placebo groups. All laboratory values remained within normal reference ranges. Blood and urine NMN and NAD+ metabolites rose dose-dependently. This is the most comprehensive safety profile published for oral NMN in humans to date, providing confidence for doses up to at least 1,250 mg as a single dose and 500 mg/day as a chronic dose.\n\nDose-Finding Physical Performance RCT (Yi et al., 2023)\n\nThis multicenter, double-blind, placebo-controlled trial enrolled 80 healthy adults aged 40–65 years across four groups: placebo, 300, 600, or 900 mg/day NMN for 60 days [4]. Primary outcomes were NAD+ metabolite levels; secondary outcomes included physical performance tests (grip strength, timed-up-and-go, 6-minute walk test) and subjective fatigue. Blood NAD+ metabolites rose significantly in all NMN groups versus placebo. On physical performance measures, the 600 mg/day group showed the most consistent improvements, outperforming both 300 mg and 900 mg groups — suggesting a U-shaped dose-response. The 900 mg group showed no additional benefit, possibly due to metabolic saturation or feedback regulation. Grip strength improvements reached statistical significance at 600 mg (p<0.05). No serious adverse events occurred. Limitation: 60 days may be too short to observe the full range of NAD+-mediated effects.\n\nOlder Adults with Diabetes (Akasaka et al., 2023)\n\nThis prospective, double-blind, placebo-controlled trial enrolled 30 older adults (mean age ~70) with type 2 diabetes and impaired physical performance (Short Physical Performance Battery score ≤9) [5]. Participants received 250 mg/day NMN or placebo for 12 weeks on top of standard diabetes care. The NMN group showed significantly greater improvements in grip strength (p<0.05) and SPPB total score (p<0.05) compared to placebo. Blood NAD+ metabolites rose significantly in the NMN group. HbA1c and fasting glucose showed a trend toward improvement that did not reach significance at this sample size (n=30). No serious adverse events occurred. This trial is notable for demonstrating benefits specifically in an older, clinically relevant population — the demographic most likely to be NAD+-depleted and most in need of functional interventions.\n\nNMN vs. NR Comparative Review (Soares Alegre & Pastore, 2023)\n\nThis narrative review compared the evidence base, metabolic pathways, and bioavailability of NMN and NR as NAD+ precursors [6]. Key findings: both precursors reliably raise blood NAD+ metabolites in published human trials. NMN is one step closer to NAD+ in the biosynthetic pathway, which may confer advantages in tissues with active Slc12a8-type transporters. NR must first be converted to NMN before NAD+ synthesis. Dietary sources of NMN exist (edamame ~1.88 mg/100g, broccoli ~0.25–1.12 mg/100g) but are pharmacologically negligible. The review notes that the clinical evidence base for both precursors is growing rapidly but remains limited in scale and duration, with most trials spanning 8–12 weeks and fewer than 100 participants. Head-to-head comparative trials in humans are lacking, making definitive claims about superiority premature.\n\nLong-Term Safety and Metabolism (Yamaguchi et al., 2024) …","deepTruncated":true,"references":[{"id":"1","title":"Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men","authors":"Irie J, Inagaki E, Fujita M, Nakaya H, Mitsuishi M, Yamaguchi S, Yamashita K, Shigaki S, Ono T, Yukioka H, Okano H, Nabeshima YI, Imai SI, Yasui M, Tsubota K, Itoh H","year":2020,"journal":"Endocrine Journal","pmid":"31685720","url":"https://pubmed.ncbi.nlm.nih.gov/31685720/"},{"id":"2","title":"Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women","authors":"Yoshino M, Yoshino J, Kayser BD, Patti GJ, Franczyk MP, Mills KF, Sindelar M, Pietka T, Patterson BW, Imai SI, Klein S","year":2021,"journal":"Science","pmid":"33888596","url":"https://pubmed.ncbi.nlm.nih.gov/33888596/"},{"id":"3","title":"Safety evaluation of β-nicotinamide mononucleotide oral administration in healthy adult men and women","authors":"Fukamizu Y, Uchida Y, Shigekawa A, Sato T, Kosaka H, Sakurai T","year":2022,"journal":"Scientific Reports","pmid":"36002548","url":"https://pubmed.ncbi.nlm.nih.gov/36002548/"},{"id":"4","title":"The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial","authors":"Yi L, Maier AB, Tao R, Lin Z, Vaidya A, Pendse S, Thasma S, Andhalkar N, Avhad G, Kumbhar V","year":2023,"journal":"Geroscience","pmid":"36482258","url":"https://pubmed.ncbi.nlm.nih.gov/36482258/"},{"id":"5","title":"Effects of nicotinamide mononucleotide on older patients with diabetes and impaired physical performance: A prospective, placebo-controlled, double-blind study","authors":"Akasaka H, Nakagami H, Sugimoto K, Yasunobe Y, Minami T, Fujimoto T, Yamamoto K, Hara C, Shiraki A, Nishida K, Asano K, Kanou M, Yamana K, Imai SI, Rakugi H","year":2023,"journal":"Geriatrics & Gerontology International","pmid":"36443648","url":"https://pubmed.ncbi.nlm.nih.gov/36443648/"},{"id":"6","title":"NAD+ Precursors Nicotinamide Mononucleotide (NMN) and Nicotinamide Riboside (NR): Potential Dietary Contribution to Health","authors":"Soares Alegre GF, Pastore GM","year":2023,"journal":"Current Nutrition Reports","pmid":"37273100","url":"https://pubmed.ncbi.nlm.nih.gov/37273100/"},{"id":"7","title":"Safety and efficacy of long-term nicotinamide mononucleotide supplementation on metabolism, sleep, and nicotinamide adenine dinucleotide biosynthesis in healthy, middle-aged Japanese men","authors":"Yamaguchi S, Irie J, Mitsuishi M, Uchino Y, Nakaya H, Takemura R, Inagaki E, Kosugi S, Okano H, Yasui M, Tsubota K, Hayashi K, Yoshino J, Itoh H","year":2024,"journal":"Endocrine Journal","pmid":"38191197","url":"https://pubmed.ncbi.nlm.nih.gov/38191197/"}],"wordCount":1886,"source":{"path":"src/content/topics/nmn/nad-precursor-and-longevity.md"},"citeAs":"“Does NMN improve insulin sensitivity, physical performance and healthy aging?.” What's Healthy and Why. https://whatshealthyandwhy.com/nmn/nad-precursor-and-longevity","notice":"General information backed by peer-reviewed research, not medical advice."}